Pharma CEO Guide to Market Access Operations
Market access has become one of the most consequential determinants of commercial success in the pharmaceutical industry. A drug that achieves FDA approval but fails to obtain favorable formulary placement, secure adequate reimbursement, or overcome patient access barriers will underperform its clinical potential regardless of the strength of its efficacy and safety data. Pharma CEOs who understand this dynamic and invest accordingly in market access operations launch more successfully and sustain revenue growth more durably than those who treat market access as a downstream commercial function.
This guide covers how to build a market access operation that positions products effectively across the payer environment, supports successful launches, and sustains commercial performance over the product lifecycle.
Structuring the HEOR and Health Economics Evidence Generation Program
Health Economics and Outcomes Research provides the evidentiary foundation for market access. Payers, particularly pharmacy benefit managers, integrated delivery networks, and government formulary committees, make coverage and reimbursement decisions based not only on clinical efficacy but on the value of a therapy relative to alternatives: how does the treatment affect total healthcare costs, patient quality of life, and health system resource utilization?
Build your HEOR program with market access objectives driving the research agenda. The most common HEOR failure mode is a research program designed by academic instinct rather than payer decision-making need. Payers want to know: what is the total cost of disease management with and without this therapy, what is the budget impact of formulary inclusion at various patient uptake scenarios, and how does this therapy’s value compare to the alternatives they are currently covering?
HEOR research should begin in parallel with Phase 3 clinical development, not after approval. Health-related quality of life instruments embedded in Phase 3 trials provide patient-reported outcome data that supports value claims in market access submissions. Economic modeling work should begin during Phase 2 when clinical parameters are becoming clearer, so that the models are ready for payer engagement well before launch.
The HEOR team should maintain close collaboration with the market access and medical affairs teams throughout the development and commercialization process. HEOR evidence that is generated without understanding the specific formulary barriers and payer objections you will face is less useful than evidence designed with those specific questions in mind. Build structured feedback loops between your market access team, which is engaging payers and hearing their specific concerns, and your HEOR team, which is designing the evidence to address those concerns.
Managing Payer Engagement Workflows
Payer engagement is the commercial outreach function that translates HEOR evidence and clinical data into formulary placement and coverage decisions. Effective payer engagement requires a structured, relationship-based workflow that begins early in the product lifecycle and sustains through post-launch coverage maintenance.
Pre-launch payer engagement should begin 18 to 24 months before anticipated approval for products targeting commercial markets. At this stage, the primary objectives are to understand the current treatment landscape and payer perspectives, present early clinical data and preliminary health economic modeling, identify the specific formulary criteria and evidence requirements that will govern formulary review, and build relationships with formulary committee members and medical directors.
Payer engagement workflows require clear segmentation of the payer landscape. Commercial payers, including national PBMs such as Express Scripts, CVS Caremark, and OptumRx, represent the largest covered lives and the most influential formulary decisions for commercially insured patients. Integrated delivery networks and health system pharmacy committees influence formulary decisions for their employed physician and hospital-based prescribers. Medicare Part D plan sponsors and Medicaid managed care organizations govern access for government-insured populations with different coverage frameworks and pricing dynamics.
Build a payer engagement calendar that tracks planned interactions with each tier of payer by timeline to launch. Map the formulary review cycles for your top payer accounts: most major PBMs conduct annual formulary reviews with defined submission and decision timelines. Missing these windows delays formulary access by a full year.
Document payer engagement systematically. A payer database that captures engagement history, formulary status, coverage criteria, objections raised, and commitments made is a critical operational asset for continuity of payer relationships across account manager transitions and for consistent communication with the same payer across multiple product teams.
Building Formulary Positioning Operations
Formulary positioning operations translate payer engagement into actual formulary status: the tier placement, coverage criteria, and prior authorization or step therapy requirements that determine how accessible a product is to patients in a given plan.
Favorable formulary status varies by product category. For a specialty product, preferred formulary status without restrictive prior authorization criteria is the gold standard. For a primary care product, first-tier or second-tier placement with no step therapy requirements maximizes patient access and minimizes prescription abandonment. The specific formulary outcome that matters most varies by product and competition set.
Formulary negotiation involves both clinical value discussions and financial arrangements, specifically rebate agreements that provide payers with financial consideration in exchange for favorable formulary positioning. Managing rebate strategy is a collaborative process between market access and finance leadership: the rebate level must be set at a point that achieves the formulary positioning necessary for commercial success while maintaining the net price economics that support revenue and profitability targets.
Formulary status monitoring is an ongoing operational requirement post-launch. Formulary decisions change annually, and a product that achieves preferred formulary status at launch may face a formulary challenge 12 to 18 months later when a competitor enters or when a payer renegotiates its coverage portfolio. Build a formulary monitoring workflow that tracks the formulary status of your products across your covered lives accounts on a quarterly basis and generates early warning of potential coverage challenges.
Coordinating Patient Assistance and Hub Services
Even with favorable formulary status, patient access barriers remain for many patients in the form of high out-of-pocket costs, complex prior authorization requirements, and specialty pharmacy logistics. Patient assistance and hub services operations address these barriers and are critical for specialty products where out-of-pocket cost, prior authorization complexity, and specialty pharmacy requirements create significant prescription abandonment risk.
Patient assistance programs, including co-pay assistance programs for commercially insured patients and free drug programs for uninsured or underinsured patients, reduce the financial barriers to access. Managing these programs requires compliance with anti-kickback and other regulatory requirements, as well as operational infrastructure for eligibility verification, enrollment processing, co-pay card redemption, and program reporting.
Hub services provide the case management, prior authorization support, benefits investigation, and patient counseling functions that help patients navigate the access and adherence challenges associated with specialty products. Hubs operate as outsourced patient support services: your company contracts with a hub services organization that operates under your brand and following your service standards.
Hub operations governance requires active engagement from your market access and commercial leadership, not just contract management. Define the service level standards the hub must meet: time from prescription submission to first fill, prior authorization success rate, patient satisfaction scores, and case management contact completion rates. Review hub performance against these standards monthly and build escalation protocols for systemic performance failures.
For related commercial operations context, the pharma commercial ops guide covers the broader commercial organization, while pharma regulatory affairs ops addresses the regulatory dimensions of product approval and lifecycle management.
Managing Global Market Access for Multi-Country Launches
For pharmaceutical companies launching in multiple markets, global market access operations introduce significant additional complexity: each country has distinct health technology assessment requirements, reimbursement frameworks, pricing regulations, and cultural norms for payer engagement.
The major HTA authorities, including NICE in the UK, HAS in France, IQWiG in Germany, and NICE Canada, each have specific evidence requirements, submission formats, and decision timelines. Navigating these systems effectively requires dedicated country-specific market access expertise, either through internal global market access teams or through external consultants with country-specific regulatory and payer relationships.
International reference pricing is one of the most significant operational challenges in multi-country launches. Many countries use the prices set in other markets as a reference when making their own price determinations. Launching at a high price in one country can constrain negotiating flexibility in reference pricing countries. Sequencing your launch geographies and managing the reference pricing implications of each launch decision requires sophisticated economic modeling and strategic coordination.
Build a global market access governance process that aligns global strategy, country-specific execution, and pricing decisions across your international markets. This governance should include clear authority matrices defining which decisions can be made at the country level versus which require regional or global leadership alignment.
Building a Market Access Operations Team That Drives Launch Success
The market access team structure and capabilities required to execute a successful launch have grown substantially as the payer environment has become more complex. Modern market access teams need capabilities spanning health economics and outcomes research, payer account management, contract and rebate management, patient services, and global market access.
For pre-commercial companies preparing for a first product launch, building this team early is among the most important operational priorities. Market access professionals with launch experience are in high demand: recruit this talent 18 to 24 months before anticipated approval to ensure your team has time to build payer relationships and develop the evidence package before launch.
Market access leadership, typically a VP or SVP of Market Access, should sit at the executive leadership table alongside commercial, medical affairs, and regulatory affairs leadership. Market access strategy is a cross-functional endeavor that cannot be executed effectively from a secondary organizational position.
Build the data infrastructure to support market access operations: a payer account management system that tracks engagement, formulary status, and contract terms; a patient services data system that tracks enrollment, prior authorization outcomes, and abandonment rates; and an analytics platform that integrates formulary data, market access metrics, and prescription data to provide a complete picture of access performance across the market.
The pharma CEO who treats market access as a core strategic capability and invests in building the evidence, relationships, and operations to support it creates a competitive advantage that sustains commercial performance through patent life and beyond.
Related Reading
For further context, explore Pharma CEO Guide to Business Development Operations and Pharma CEO Guide to Business Operations Management.